Search

You searched for "referrals"

1605 results found

Capacity building for ophthalmic nursing in Ghana, Botswana and Tanzania

2 December 2019 | | EYE - General
Ophthalmic nurses (ON) have been the backbone of eye health services in Africa since the mid-20th century and remain the largest single cadre of allied ophthalmic personnel in Commonwealth countries in Africa. Numbers are currently estimated at between 3500 and...

The fragile p-value

5 October 2020 | | EYE - General
Abdus Samad Ansari explores the limitation of the p-value and the application of the fragility index in clinical trials. Clinical trials and tribulations? The restoration of vision or more purely the gift of sight is an aspect of care that...

Grading of ocular inflammation in uveitis: an overview

1 February 2016 | | EYE - Vitreo-Retinal
Anterior uveitis is the commonest form of uveitis, which can lead to severe morbidity if not treated appropriately [1]. Data from general ophthalmology practices suggest around 90% of uveitis encountered by comprehensive ophthalmologists is anterior uveitis [2]. Intermediate (vitreous), posterior...

Intravitreal injections delivered by ophthalmic clinical nurse specialists

1 June 2015 | | EYE - Vitreo-Retinal
Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

1 February 2015 | | EYE - Vitreo-Retinal
The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...

Corporate M&A pace gathers momentum

1 October 2019 | | EYE - General
Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

All systems go for Oriel - final approval granted to make new centre a reality

24 November 2022
Plans for Oriel, a new state-of-the-art eye care, research and education centre, have been given the green light.

EyeLogbook

1 June 2016 | | EYE - General
This issue we’re covering the recently updated EyeLogbook (www.eyelogbook.co.uk), the Royal College of Ophthalmologist’s (RCO) online surgical logbook. Back in March 2016 a fully re-designed version of the site was released. Not only does the new version bring a beautifully...

Glasgow eye department continues to disrupt ocular simulation training through novel DRV system - the first of many?

24 November 2022 | | EYE - General, EYE - Imaging
Ongoing technological developments are enabling continuous progress to be made across all aspects of medical simulation training. This is particularly true within the field of ophthalmology, where surgical training advancements have enabled the role of simulation to expand dramatically over...

Glasgow eye department continues to disrupt ocular simulation training through novel DRV system - the first of many?

28 November 2022 | | EYE - Imaging, EYE - General
Ongoing technological developments are enabling continuous progress to be made across all aspects of medical simulation training. This is particularly true within the field of ophthalmology, where surgical training advancements have enabled the role of simulation to expand dramatically over...

Management of DMO and PDR in 2019

10 October 2019 | | EYE - Vitreo-Retinal, EYE - General
An evidence-based approach to the management of diabetic macular oedema (DMO) and proliferative diabetic retinopathy (PDR) in 2019 was outlined by Sobha Sivaprasad, UK, in presentations during the Diabetic Retina scientific session September 6 2019, at the 19th European Society...

LambdaVision aims to refine process for in-space manufacturing of artificial retinas through ISS National Lab-sponsored investigation

1 February 2024 | ISS, retinal, artificial, LambdaVision, industry, innovation, retinitis pigmentosa, RP
Approximately 1.5 million people worldwide are affected by retinitis pigmentosa, a rare genetic disorder that causes vision loss. Currently there is no cure, but researchers from LambdaVision are turning to the International Space Station (ISS) National Laboratory to look for...